BoneFDA Approved

PTH (1-34) Analogs

Subcutaneous injection

Overview

PTH (1-34) analogs, including teriparatide and abaloparatide, are synthetic peptides corresponding to the 34 N-terminal amino acids of human parathyroid hormone. These agents bind to the PTH1 receptor on osteoblasts and osteocytes, stimulating bone formation through activation of intracellular signaling pathways including cyclic AMP and protein kinase A.

Mechanism of Action

Intermittent administration preferentially stimulates osteoblastic bone formation over osteoclastic resorption, increasing bone mass and reducing fracture risk. The anabolic effect distinguishes these agents from antiresorptive therapies such as bisphosphonates..

Research Summary & Key Findings

Teriparatide was FDA approved in 2002 based on pivotal trials demonstrating significant reductions in vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. Abaloparatide received FDA approval in 2017 following the ACTIVE trial, which showed superior bone mineral density gains and fracture reduction compared to placebo and teriparatide at certain skeletal sites. Both agents carry a boxed warning regarding osteosarcoma risk based on rodent studies, though no causal relationship has been established in humans.

Clinical Status

FDA Approved

PTH (1-34) Analogs has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection

Related Peptides in Bone

Teriparatide (Forteo)

FDA Approved

A recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). When administered intermittently...

View details

Abaloparatide (Tymlos)

FDA Approved

A synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34) that selectively activates ...

View details

Calcitonin

FDA Approved

A 32-amino acid peptide hormone naturally produced by parafollicular C-cells of the thyroid gland. Calcitonin inhibits o...

View details

Vosoritide (Voxzogo)

FDA Approved

A C-type natriuretic peptide (CNP) analog that acts as an agonist at the natriuretic peptide receptor B (NPR-B) on growt...

View details

Find a Provider

Find a verified provider who offers PTH (1-34) Analogs therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply PTH (1-34) Analogs.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.